Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2

Status

Completed 4Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gastrointestinal 1

Conditions

Breast Neoplasms 6Sarcoma, Alveolar Soft Part 1Colorectal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × Loperamide × Clear all
NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Eli Lilly and Company

Phase 1 Active not recruiting
198 enrolled
Breast

Breast Neoplasms

NCT04172597 2024-03-13

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Spectrum Pharmaceuticals, Inc

Phase 2 Terminated
1 enrolled 2 charts
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT04366713 2023-02-10

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Puma Biotechnology, Inc.

Phase 2 Completed
6 enrolled 8 charts
Breast

Breast Neoplasms

NCT05252546 2022-12-23

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled
Breast

Breast Neoplasms

NCT02400476 2022-05-06

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Puma Biotechnology, Inc.

Phase 2 Completed
563 enrolled 16 charts
Breast

Breast Neoplasms

NCT02441946 2020-06-17

neoMONARCH

Eli Lilly and Company

Phase 2 Completed
224 enrolled 20 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡